Loading clinical trials...
Loading clinical trials...
ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
Clinical Trial Site
Birmingham, Alabama, United States
Clinical Trial Site
Gilbert, Arizona, United States
Clinical Trial Site
San Francisco, California, United States
Clinical Trial Site
Baltimore, Maryland, United States
Clinical Trial Site
Boston, Massachusetts, United States
Clinical Trial Site
Minneapolis, Minnesota, United States
Clinical Trial Site
New York, New York, United States
Clinical Trial Site
Winston-Salem, North Carolina, United States
Clinical Trial Site
Oklahoma City, Oklahoma, United States
Clinical Trial Site
Philadelphia, Pennsylvania, United States
Start Date
April 26, 2021
Primary Completion Date
April 1, 2027
Completion Date
April 1, 2027
Last Updated
February 17, 2026
150
ESTIMATED participants
Lead Sponsor
Alnylam Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions